Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 14/20 | 0.48 |
| ▸ | GCGR | P47871 | 5/20 | 0.42 |
| ▸ | ADCY6 | O43306 | 3/20 | 0.42 |
| ▸ | ADCY3 | O60266 | 3/20 | 0.42 |
| ▸ | ADCY9 | O60503 | 3/20 | 0.42 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.42 |
| ▸ | ADCY8 | P40145 | 3/20 | 0.42 |
| ▸ | ADCY7 | P51828 | 3/20 | 0.42 |
| ▸ | ADCY2 | Q08462 | 3/20 | 0.42 |
| ▸ | ADCY1 | Q08828 | 3/20 | 0.42 |
| ▸ | ADCY4 | Q8NFM4 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102223 | 0.90 | GCG (0.50) | GCGGCGRADCY6ADCY3ADCY9 | |
| SCHEMBL3109777 | 0.87 | GCG (0.52) | GCGGCGRADCY6ADCY3ADCY9 | |
| SCHEMBL3102175 | 0.85 | GCG (0.39) | GCGMEN1ALDH1A1PKMHTT | |
| SCHEMBL3099433 | 0.85 | GCG (0.48) | GCGGCGR | |
| SCHEMBL3090880 | 0.85 | MEN1 (0.45) | GCGGCGRADCY6ADCY3ADCY9 | |
| SCHEMBL3099976 | 0.83 | GCG (0.48) | GCGGCGRADCY6ADCY3ADCY9 | |
| SCHEMBL3106816 | 0.81 | GCG (0.45) | GCGGCGRADCY6ADCY3ADCY9 | |
| SCHEMBL3106645 | 0.81 | GCG (0.44) | GCGGCGRALDH1A1 | |
| SCHEMBL3095767 | 0.79 | GCG (0.51) | GCGGCGR | |
| SCHEMBL3113197 | 0.79 | GCG (0.47) | GCGGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | GCG 11/4885GCGR 3/4885ADCY6 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.